Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 246

1.

5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) effect on glucose production, but not energy metabolism, is independent of hepatic AMPK in vivo.

Hasenour CM, Ridley DE, Hughey CC, James FD, Donahue EP, Shearer J, Viollet B, Foretz M, Wasserman DH.

J Biol Chem. 2014 Feb 28;289(9):5950-9. doi: 10.1074/jbc.M113.528232. Epub 2014 Jan 8.

3.

Enhanced activation of cellular AMPK by dual-small molecule treatment: AICAR and A769662.

Ducommun S, Ford RJ, Bultot L, Deak M, Bertrand L, Kemp BE, Steinberg GR, Sakamoto K.

Am J Physiol Endocrinol Metab. 2014 Mar;306(6):E688-96. doi: 10.1152/ajpendo.00672.2013. Epub 2014 Jan 14.

4.

Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats.

Bergeron R, Previs SF, Cline GW, Perret P, Russell RR 3rd, Young LH, Shulman GI.

Diabetes. 2001 May;50(5):1076-82.

5.
6.

Short-term adenosine monophosphate-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside treatment increases the sirtuin 1 protein expression in skeletal muscle.

Suwa M, Nakano H, Radak Z, Kumagai S.

Metabolism. 2011 Mar;60(3):394-403. doi: 10.1016/j.metabol.2010.03.003. Epub 2010 Apr 1.

PMID:
20362304
7.
8.

5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside renders glucose output by the liver of the dog insensitive to a pharmacological increment in insulin.

Camacho RC, Lacy DB, James FD, Donahue EP, Wasserman DH.

Am J Physiol Endocrinol Metab. 2005 Dec;289(6):E1039-43. Epub 2005 Jul 26.

9.

Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations.

Halseth AE, Ensor NJ, White TA, Ross SA, Gulve EA.

Biochem Biophys Res Commun. 2002 Jun 21;294(4):798-805.

PMID:
12061777
10.

AMP-activated protein kinase controls metabolism and heat production during embryonic development in birds.

Walter I, Hegarty B, Seebacher F.

J Exp Biol. 2010 Sep 15;213(Pt 18):3167-76. doi: 10.1242/jeb.043349.

11.

AMPK activation with AICAR provokes an acute fall in plasma [K+].

Zheng D, Perianayagam A, Lee DH, Brannan MD, Yang LE, Tellalian D, Chen P, Lemieux K, Marette A, Youn JH, McDonough AA.

Am J Physiol Cell Physiol. 2008 Jan;294(1):C126-35. Epub 2007 Nov 14.

12.

Defining the contribution of AMP-activated protein kinase (AMPK) and protein kinase C (PKC) in regulation of glucose uptake by metformin in skeletal muscle cells.

Turban S, Stretton C, Drouin O, Green CJ, Watson ML, Gray A, Ross F, Lantier L, Viollet B, Hardie DG, Marette A, Hundal HS.

J Biol Chem. 2012 Jun 8;287(24):20088-99. doi: 10.1074/jbc.M111.330746. Epub 2012 Apr 17.

13.

Role of adenosine 5'-monophosphate-activated protein kinase in interleukin-6 release from isolated mouse skeletal muscle.

Glund S, Treebak JT, Long YC, Barres R, Viollet B, Wojtaszewski JF, Zierath JR.

Endocrinology. 2009 Feb;150(2):600-6. doi: 10.1210/en.2008-1204. Epub 2008 Sep 25.

PMID:
18818284
14.

Stimulation of glucose transport in response to activation of distinct AMPK signaling pathways.

Jing M, Cheruvu VK, Ismail-Beigi F.

Am J Physiol Cell Physiol. 2008 Nov;295(5):C1071-82. doi: 10.1152/ajpcell.00040.2008. Epub 2008 Aug 13.

15.

AMP-activated protein kinase-independent inhibition of hepatic mitochondrial oxidative phosphorylation by AICA riboside.

Guigas B, Taleux N, Foretz M, Detaille D, Andreelli F, Viollet B, Hue L.

Biochem J. 2007 Jun 15;404(3):499-507.

16.

Impact of in vivo fatty acid oxidation blockade on glucose turnover and muscle glucose metabolism during low-dose AICAR infusion.

Christopher M, Rantzau C, Chen ZP, Snow R, Kemp B, Alford FP.

Am J Physiol Endocrinol Metab. 2006 Nov;291(5):E1131-40. Epub 2006 Jun 13.

17.

Effect of the AMP-kinase modulators AICAR, metformin and compound C on insulin secretion of INS-1E rat insulinoma cells under standard cell culture conditions.

Langelueddecke C, Jakab M, Ketterl N, Lehner L, Hufnagl C, Schmidt S, Geibel JP, Fuerst J, Ritter M.

Cell Physiol Biochem. 2012;29(1-2):75-86. doi: 10.1159/000337589. Epub 2012 Mar 1.

18.

5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation.

Guigas B, Bertrand L, Taleux N, Foretz M, Wiernsperger N, Vertommen D, Andreelli F, Viollet B, Hue L.

Diabetes. 2006 Apr;55(4):865-74.

19.

Knockout of the alpha2 but not alpha1 5'-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle.

Jørgensen SB, Viollet B, Andreelli F, Frøsig C, Birk JB, Schjerling P, Vaulont S, Richter EA, Wojtaszewski JF.

J Biol Chem. 2004 Jan 9;279(2):1070-9. Epub 2003 Oct 21.

20.

AMPK stimulation increases LCFA but not glucose clearance in cardiac muscle in vivo.

Shearer J, Fueger PT, Rottman JN, Bracy DP, Martin PH, Wasserman DH.

Am J Physiol Endocrinol Metab. 2004 Nov;287(5):E871-7. Epub 2004 Jul 20.

Supplemental Content

Support Center